ClinicalTrials.gg
CompletedNCT04575311Updated May 24, 2024

A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers

A Phase 1 interventional study of AB680 and Placebo in Healthy Volunteers, sponsored by Arcus Biosciences, Inc.. Completed at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-24.

Sponsored by Arcus Biosciences, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

A Double-Blind, Randomized, Placebo-Controlled, Single Ascending Dose Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers.

Read the detailed description

The study will evaluate minimum of 2 dose levels of AB680 in 8 participants per cohort. Cohorts will be gender-balanced to the extent possible, and will be randomized 3:1, active vs placebo, respectively.

The participants will be closely observed for the first 48 hours following drug administration to monitor the general tolerability of AB680.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Arcus Biosciences, Inc. is the lead sponsor of 32 studies on the registry; 4 are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants aged 18 to 55 years, inclusive, at screening
  • 18 to 32 kilograms/m\^2 inclusive
  • Willing and able to sign
  • Negative tests for surface antigen, anti- virus, and (HIV)-1 and HIV-2 antibody at screening
  • Healthy as determined by pre-study screening

Exclusion criteria

Exclusion Criteria:

  • History of drug and/or food allergies
  • Positive drug and alcohol screen at screening and (each) admission to the clinical research center.
  • Participation in a drug study within 60 days prior to (the first) drug administration in the current study. Participation in more than 4 other drug studies in the 12 months prior to (the first) drug administration in the current study
  • Participants who have significant infection or known inflammatory process on screening or admission
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
32 participants (actual)

Study arms

  • Active comparator
    Active: Dose Escalation

    Participants will receive a single oral dose of AB680 at one of two ascending dose levels. Assignment to receive AB680 will be random.

    Drug: AB680

  • Placebo comparator
    Placebo: Dose Escalation

    Participants will receive matching placebo as a single oral dose. Assignment to receive matching placebo will be random.

    Other: Placebo

Interventions

  • DrugAB680

    AB680 is a Cluster of Differentiation (CD)73 Inhibitor

  • OtherPlacebo

    Matching Placebo

06

What researchers measure

Primary outcomes

  1. AB680 Peak Plasma Concentration (Cmax)

    Cmax as measured by the Area Under Concentration-Time Curve from Plasma Collection and Analysis.

    Time frame: Pre-dose; from First Dose Date to 15 Days After the Last Dose of AB680

  2. AB680 Time of Peak Concentration (Tmax)

    Tmax as measured by the Time to Maximum Concentration-Time Curve from Plasma Collection and Analysis

    Time frame: Pre-dose; from First Dose Date to 15 Days After the Last Dose of AB680

  3. Area under the plasma concentration-time curve from time zero to t hours (AUC 0-t) of AB680

    Time frame: Pre-dose; from First Dose Date to 15 Days After the Last Dose of AB680

Secondary outcomes

  1. Number of participants with Treatment Emergent Adverse Events (TEAEs)

    Number of participants with TEAEs as assessed by CTCAE v5.0.

    Time frame: From First Dose Date to 15 Days After the Last Dose of AB680

Other outcomes

  1. Pharmacodynamic (PD) Effects of AB680

    Enzymatic Activity of CD73 measured in participant blood samples.

    Time frame: Pre-dose; from First Dose Date to 15 Days After the Last Dose of AB680]

07

Study locations

1 site
  • Nucleus Network
    Melbourne, Victoria, Australia
08

References and documents

Individual participant data

Plan to share: Yes — Arcus will provide access to individual de-identified participant data and related study documents (e.g., protocol, Statistical Analysis Plan [SAP], Clinical Study Report [CSR]) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. For more information, please visit our website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Data sharing details ↗ · trials.arcusbio.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in Sep 2021, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2020
First posted
Oct 5, 2020
StartActual
Oct 20, 2020
Primary completionActual
Sep 22, 2021
CompletionActual
Sep 22, 2021
Last update
May 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04575311
Responsible party
Sponsor
First posted
Oct 5, 2020
Start date
Oct 20, 2020
Primary completion
Sep 22, 2021
Completion
Sep 22, 2021
Last update
May 24, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Quemliclustat

Start the discussion